Qsymia

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Endpoints
Vivus
Qsymia
weight loss
ICER
Novo Nordisk
Saxenda
Wegovy
Flag link:
A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
Endpoints
Vivus
Qsymia
teens
FDA
obesity
Flag link:
Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug
Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug
Xconomy
Vivus
Qsymia
Pancreaze
Janssen
Flag link:
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Orexigen struggles to stay afloat as obesity market stagnates
Orexigen struggles to stay afloat as obesity market stagnates
BioPharma Dive
Orexigen
obesity
Contrave
Vivus
Qsymia
Takeda
Flag link:
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Arena Pharmaceuticals
obesity
Orexigen
Belviq
Eisai
Vivus
Novo Nordisk
Qsymia
Victoza
Flag link:
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Fierce Pharma Marketing
obesity
Vivus
Orexigen
Contrave
Qsymia
Takeda
Flag link:
Vivus- Were Qsymia Patents Strong Enough? Actavis Stance Questions That
Vivus- Were Qsymia Patents Strong Enough? Actavis Stance Questions That
Seeking Alpha
Vivus
Qsymia
patents
Actavis
Flag link:
The 3 Most Disappointing Drug Launches of All Time
The 3 Most Disappointing Drug Launches of All Time
Motley Fool
drug launches
MannKind
Afrezza
Sanofi
Zaltrap
Vivus
Arena Pharmaceuticals
Qsymia
Belviq
Flag link:
Can a dwindling rep tally keep Vivus' obesity med in the game?
Can a dwindling rep tally keep Vivus' obesity med in the game?
Fierce Pharma Marketing
Vivus
obesity
drug reps
Qsymia
Flag link:
Express Scripts excludes 20 more drugs from 2016 coverage
Express Scripts excludes 20 more drugs from 2016 coverage
Yahoo/Reuters
Express Scripts
formulary
Vivus
Qsymia
AstraZeneca
Onglyza
Flag link:
Lagging Qsymia sales force Vivus to cut sales force again, this time by 50%
Lagging Qsymia sales force Vivus to cut sales force again, this time by 50%
Seeking Alpha
Vivus
Qsymia
layoffs
Flag link:
Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap
Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap
Fierce Pharma Marketing
obesity
Takeda
Contrave
Orexigen
Vivus
Qsymia
Eisai
Belviq
Arena Pharmaceuticals
Flag link:
Vivus's Products Show Greater Coverage From Top U.S. Health Insurance Providers
Vivus's Products Show Greater Coverage From Top U.S. Health Insurance Providers
Seeking Alpha
Vivus
Stendra
Qsymia
insurers
Flag link:
Vivus-Qsymia Sales Post Modest Gain - Slow And Steady Does Not Win The Race
Vivus-Qsymia Sales Post Modest Gain - Slow And Steady Does Not Win The Race
Seeking Alpha
Vivus
Qsymia
Flag link:
Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate
Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate
Seeking Alpha
Vivus
Qsymia
obesity
Orexigen
Arena Pharmaceuticals
Belviq
Contrave
Flag link:
Vivus - Qsymia Script Sales Flat Again - Should Vivus Concentrate On Stendra?
Vivus - Qsymia Script Sales Flat Again - Should Vivus Concentrate On Stendra?
Seeking Alpha
Vivus
Qsymia
Stendra
obesity
erectile dysfunction
Flag link:
VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia
VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia
Yahoo
Vivus
Qsymia
patents
Flag link:

Pages